Antiviral Strategies Against HEV

About this project

In close cooperation with colleagues in the field of structural biology (Prof. Krey's team at the University of Lübeck), we have successfully identified the first potent neutralizing human antibodies against HEV. This achievement was made possible by isolating HEV-specific memory B cells from convalescent patients' blood. These antibodies have undergone comprehensive examinations, including assessments of their binding affinity, antigen binding sites, and neutralization capabilities across various HEV genotypes. Additionally, their protective role in a mouse model has been confirmed (manuscript in preparation). Currently, we are closely collaborating with our partners to further advance the clinical development of these antibodies. Furthermore, we are conducting investigations into alternative methods for administering antibodies, including mRNA-based approaches.